Acute myeloid leukemia (AML) is a type of blood cancer that begins in the bone marrow, the soft tissue inside bones where blood cells are produced.
It affects immature cells that normally develop into healthy blood cells, including red blood cells, white blood cells, and platelets.
In AML, abnormal cells called myeloid blasts grow and multiply without developing properly. These cells can accumulate in the bone marrow and interfere with the production of normal blood cells. As a result, people with AML may experience fatigue, infections, bruising, or bleeding.
AML is classified as an acute leukemia because it generally develops and progresses quickly. The condition can affect adults of different ages, although it is more common among older adults. In some cases, it develops after certain blood disorders or previous cancer treatments.
Risk Factors and Possible Causes
The exact cause of AML is not always known. Several factors may be associated with an increased likelihood of developing the condition, including:
Older age, as the likelihood of AML generally increases with age.
Certain genetic changes that affect blood cell development.
Previous exposure to specific chemotherapy drugs or radiation.
Some inherited conditions that affect blood or bone marrow.
Certain blood disorders that may develop into AML.
Having a risk factor does not mean a person will develop AML. Some people diagnosed with the condition have no identifiable risk factors.
How AML Develops
AML begins when changes occur in the genetic material of developing blood cells. These changes can affect how cells grow, divide, and mature.
As abnormal cells accumulate, they may crowd out healthy cells in the bone marrow. This can reduce the production of normal blood cells and lead to symptoms that require medical evaluation.
Importance
Understanding AML matters because the condition can develop rapidly and affect several important functions of the body. Early recognition of symptoms and timely medical evaluation can help determine whether further testing is needed.
AML can affect everyday life through fatigue, weakness, repeated infections, and bleeding problems. These symptoms may interfere with normal activities and can sometimes resemble those of other illnesses.
Common Symptoms
Symptoms may develop over a short period and vary between individuals. Common signs include:
Persistent fatigue or weakness.
Fever or frequent infections.
Pale skin or shortness of breath.
Easy bruising or unusual bleeding.
Small red or purple spots on the skin.
Bone or joint discomfort.
Unexplained weight loss or reduced appetite.
These symptoms do not necessarily indicate leukemia. Other medical conditions can cause similar problems, so diagnosis requires appropriate medical testing.
Acute Myeloid Leukemia Diagnosis
An acute myeloid leukemia diagnosis usually involves several tests that help identify abnormal cells and determine the type of leukemia.
A complete blood count can measure the number of red blood cells, white blood cells, and platelets. A blood smear allows specialists to examine the appearance of blood cells under a microscope.
Bone marrow aspiration and biopsy may be used to collect samples for examination. Additional laboratory tests can identify genetic changes and other characteristics of the abnormal cells.
These findings help doctors classify AML and understand which treatment approaches may be appropriate.
Recent Updates
Developments in AML care from 2024 through 2026 have continued to emphasize more detailed disease classification, genetic testing, and individualized treatment planning. These approaches help medical teams consider differences between AML cases rather than treating every diagnosis as identical.
Genetic Testing and Treatment Planning
Genetic and molecular testing can identify changes within leukemia cells. These findings may help doctors understand how the disease is likely to behave and which treatment approaches may be relevant.
Testing can also help identify patients who may be eligible for particular targeted therapies or clinical trials. The results are considered alongside age, general health, disease characteristics, and treatment goals.
Acute Myeloid Leukemia Treatment Options
Acute myeloid leukemia treatment options depend on the subtype of AML, genetic findings, the person's overall health, and whether the disease is newly diagnosed or has returned.
Treatment may involve chemotherapy, targeted medicines, stem cell transplantation, or a combination of approaches.
| Treatment approach | General purpose |
|---|---|
| Chemotherapy | Destroy leukemia cells or reduce their number |
| Targeted therapy | Act on specific changes or features of leukemia cells |
| Stem cell transplant | Replace diseased blood-forming cells with healthy stem cells |
| Supportive care | Manage symptoms and complications during treatment |
| Clinical trials | Study new or modified treatment approaches |
AML Clinical Trials
AML clinical trials study new treatments, combinations of medicines, or changes to existing treatment approaches. Some trials examine treatments for newly diagnosed AML, while others focus on disease that has returned or has not responded to earlier treatment.
Eligibility depends on factors such as AML subtype, previous treatment, age, and general health. Participation involves a study protocol, and the possible benefits and risks are explained during the consent process.
AML Bone Marrow Transplant
An AML bone marrow transplant, often called a stem cell transplant, may be considered for certain patients. The procedure involves replacing blood-forming stem cells after treatment that prepares the body for transplantation.
A transplant may be considered when the risk of AML returning is significant or when other clinical factors support this approach. The decision depends on the person's health, disease characteristics, donor availability, and potential transplant-related risks.
Tools and Resources
Reliable educational resources can help people understand AML, prepare questions, and learn about diagnosis and treatment approaches.
Medical Information Resources
The following organizations provide general information about leukemia and related medical research:
National Cancer Institute (NCI): Information about AML, diagnosis, treatment, and clinical trials.
American Cancer Society (ACS): Educational material about leukemia symptoms, testing, and treatment.
National Comprehensive Cancer Network (NCCN): Patient-oriented cancer guidelines and educational resources.
ClinicalTrials.gov: A database of clinical studies, including AML clinical trials.
These resources provide general information. They do not replace an individual medical assessment.
Acute Myeloid Leukemia Specialist and Treatment Centers
An acute myeloid leukemia specialist is generally a hematologist or oncologist with experience in blood cancers. Specialists may work in hospitals or cancer centers that have facilities for leukemia diagnosis, chemotherapy, genetic testing, and stem cell transplantation.
People researching AML treatment centers or AML leukemia hospitals may review the medical team's experience with leukemia, available diagnostic facilities, transplant capabilities, and access to clinical trials.
An acute myeloid leukemia second opinion may help clarify a diagnosis, review genetic test results, or discuss treatment approaches. The timing and usefulness of another opinion depend on the medical circumstances, particularly when AML requires urgent treatment.
FAQs
What is acute myeloid leukemia treatment?
Acute myeloid leukemia treatment may involve chemotherapy, targeted medicines, stem cell transplantation, or supportive care. The treatment plan depends on the AML subtype, genetic findings, age, and general health.
How is acute myeloid leukemia diagnosis confirmed?
An acute myeloid leukemia diagnosis typically involves blood tests, examination of blood cells, bone marrow testing, and genetic or molecular analysis. These tests help confirm the disease and classify its characteristics.
What are the main acute myeloid leukemia treatment options?
Treatment options may include chemotherapy, targeted therapy, stem cell transplantation, and participation in clinical trials. Doctors determine which approaches are suitable based on individual medical findings.
What should people know about AML clinical trials?
AML clinical trials evaluate treatments or treatment combinations under a defined research protocol. Eligibility criteria, potential risks, and possible benefits vary by study.
When is an AML bone marrow transplant considered?
A bone marrow or stem cell transplant may be considered for selected patients based on disease risk, treatment response, general health, and other clinical factors. It requires careful evaluation by a transplant team.
Conclusion
Acute myeloid leukemia is a rapidly developing blood cancer that affects the production of healthy blood cells in the bone marrow. Diagnosis involves blood and bone marrow testing, including genetic analysis, to identify the disease and its characteristics. Acute myeloid leukemia treatment options may include chemotherapy, targeted therapy, stem cell transplantation, and clinical trials. Understanding AML risk factors, diagnostic methods, and treatment approaches provides a foundation for learning about this complex medical condition.